Clinical outcomes, Multiple myeloma, Relapsed/refractory disease
dx.doi.org/10.3816/CLML.2011.n.005, hdl.handle.net/1765/82196
Clinical Lymphoma, Myeloma and Leukemia
Erasmus MC: University Medical Center Rotterdam

Blade, J, Sonneveld, P, San Miguel, J.F, Sutherland, H, Hàjek, R, Nagler, A, … Orlowski, R.Z. (2011). Efficacy and safety of pegylated liposomal doxorubicin in combination with bortezomib for multiple myeloma: Effects of adverse prognostic factors on outcome. Clinical Lymphoma, Myeloma and Leukemia, 11(1), 44–49. doi:10.3816/CLML.2011.n.005